CVS vs RARE · P/E 16, rev $106.10B vs rev $350.0M
CVS Health Corp (CVS) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported CVS revenue for 2026-06-30 was $106.10B. Net income was $2.98B. Revenue was up 5.6% from 2026-03-31 to 2026-06-30. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. RARE currently screens at market cap $2.79B.
Not investment advice. Open the CVS and RARE stock pages for the full models.
Not investment advice.